• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 1Prescription drugs indicated for prevention and treatment of low bone density/osteoporosis

DrugTrade Name(s)Labeled IndicationsDosingDose Adjustments for Special Populations
Bisphosphonates
Alendronate
Source: Merck & Co., Inc., March 2010
Fosamax®Indicated for treatment and prevention of osteoporosis in postmenopausal women; increasing bone mass in men with osteoporosis; treatment of glucocorticoid(GC)-induced osteoporosis in men and women with low bone massOne 10 mg tablet, once daily, or 70mg (as tablet or oral solution) once weekly

70 mg (as tablet or oral solution) once weekly, or one 10 mg tablet daily

One 35 mg tablet weekly or one 5 mg tablet daily

One 5mg tablet daily
Treatment of postmenopausal women with osteoporosis

Treatment of men with osteoporosis

Prevention of osteoporosis in postmenopausal women

Treatment of glucocorticoid-induced osteoporosis
Ibandronate
Source: Genentech, Jan. 2010
Boniva®Indicated for treatment and prevention of osteoporosis in postmenopausal womenOne 150 mg tablet once monthly or one 2.5 mg tablet once daily or 3 mg injectable every 3 monthsNo dose adjustment necessary
RisedronateActonel®
Actonel w/calcium®
Atelvia®
Indicated for treatment and prevention of osteoporosis in postmenopausal women and glucocorticoid-induced osteoporosis; Treatment to increase bone mass in men with osteoporosisTreatment of postmenopausal women: 5 mg daily; 35 mg, weekly; 75 mg taken on two consecutive days each month; or 150 mg once monthly;
Actonel with calcium is packaged as the once weekly 35mg with 1,250 mg calcium carbonate tablets to be taken daily; Atelvia is taken once weekly after breakfast
Prevention in postmenopausal women: 5 mg daily or 35 mg weekly;
Men: 35 mg weekly; Treatment and prevention of glucocorticoid-induced osteoporosis: 5 mg daily
Zoledronic AcidReclast®Indicated for treatment and prevention of osteoporosis in postmenopausal women and glucocorticoid-induced osteoporosis; Treatment to increase bone mass in men with osteoporosisTreatment of postmenopausal women: 5mg infusion annually; prevention in postmenopausal women: 5 mg infusion bienniallyTreatment of men with osteoporosis and treatment and prevention of glucocorticoid-induced osteoporosis: 5 mg infusion annually
Selective Estrogen Receptor Modulators (SERMs)
RaloxifeneEvista®Indicated for treatment and prevention of osteoporosis in postmenopausal women60 mg tablet once dailyn/a
Peptide Hormones
TeriparatideForteo®Indicated for treatment of osteoporosis in postmenopausal women at high risk for fracture20 mcg subcutaneously once dailyTo increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or to treat men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture: same dose
Steroid Hormones
Conjugated equine estrogenPremarin®Indicated for prevention of postmenopausal osteoporosis0.3 mg tablet dailyn/a
Conjugated estrogen (CEE)/Medroxyprogesterone (MPA)Prempro®Indicated for prevention of postmenopausal osteoporosis0.3 mg CEE/1.5 mg MPA daily;0.45 CEE/1.5 mg MPA; 0.625 mg CE/2.5 mg MPA; 0.625 CEE/5 mg MPAn/a
Estradiol(E)/norgestimate(NE)Prefest®Indicated for prevention of postmenopausal osteoporosis1.0 mg E daily for 3 consecutive days; 1.0 mg E/ 0.09 mg NE daily for next 3 consecutive daysn/a
17β Estradiol/norethindrone acetateActivella®
femhrt®etc.
Indicated for prevention of postmenopausal osteoporosisActivella: 1.0 mg E.0.5 mg NE or 0.5 mg E/0.1 mg NE daily
Femhrt: 1/0.5 mg or 0.5/0.25 mg daily
n/a
17β Estradiol/levonorgestrel transdermalClimaraPro®Indicated for prevention of postmenopausal osteoporosis0.045mg estradiol/ 0.015 mg levonorgestrel delivered dailyn/a
Estradiol oralEstrace Oral®Indicated for prevention of postmenopausal osteoporosis0.5, 1 or 2 mg daily
Estradiol transdermalVivelle®
Climara®
menostar®
Indicated for prevention of postmenopausal osteoporosisVariablen/a
Biologicals
DenosumabProliaTM®Indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.60 mg injected subcutaneously every six monthsn/a

From: Introduction

Cover of Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet].
Comparative Effectiveness Reviews, No. 53.
Crandall CJ, Newberry SJ, Diamant A, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.